Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Crescent Biopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Crescent Biopharma, Inc.’s stock price such as:

• Crescent Biopharma, Inc.’s current stock price and volume
• Why Crescent Biopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for CBIO from analysts
• CBIO’s stock price momentum as measured by its relative strength

About Crescent Biopharma, Inc. (CBIO)

Before we jump into Crescent Biopharma, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Want to learn more about Crescent Biopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Crescent Biopharma, Inc..

What Caused Crescent Biopharma, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 01, 2026, there was 1 analyst who downgraded Crescent Biopharma, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Crescent Biopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Crescent Biopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Crescent Biopharma, Inc. (CBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Crescent Biopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 01, 2026, Crescent Biopharma, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Crescent Biopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Crescent Biopharma, Inc. Stock Price: Bottom Line

As of May 1, 2026, Crescent Biopharma, Inc.’s stock price is $18.140, which is down 18.91% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Crescent Biopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.